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ABSTRACT: High-resolution proton magnetic resonance spectroscopy was performed on tissue specimens from 33 patients
with astrocytic tumors (22 astrocytomas, 11 glioblastomas) and 13 patients with meningiomas. For all patients, samples of
primary tumors and their first recurrences were examined. Increased anaplasia, with respect to malignant transformation,
resulting in a higher malignancy grade, was present in 11 recurrences of 22 astrocytoma patients. Spectroscopic features of
tumor types, as determined on samples of the primary occurrences, were in good agreement with previous studies.
Compared with the respective primary astrocytomas, characteristic features of glioblastomas were significantly increased
concentrations of alanine (Ala) (p¼ 0.005), increased metabolite ratios of glycine (Gly)/total creatine (tCr) (p¼ 0.0001) and
glutamate (Glu)/glutamine (Gln) (p¼ 0.004). Meningiomas showed increased Ala (p¼ 0.02) and metabolite ratios [Gly,
total choline (tCho), Ala] over tCr (p¼ 0.001) relative to astrocytomas, and N-acetylaspartate and myo-inositol were absent.
Metabolic changes of an evolving tumor were observed in recurrent astrocytomas: owing to their consecutive assessments,
more indicators of malignant degeneration were detected in astrocytoma recurrences (e.g. Gly, p¼ 0.029; tCho, p¼ 0.034;
Glu, p¼ 0.015; tCho/tCr, p¼ 0.001) in contrast to the comparison of primary astrocytomas with primary glioblastomas. The
present investigation demonstrated a correlation of the tCho-signal with tumor progression. Significantly elevated
concentrations of Ala (p¼ 0.037) and Glu (p¼ 0.003) and metabolite ratio tCho/tCr (p¼ 0.005) were even found in
recurrent low-grade astrocytomas with unchanged histopathological grading (n¼ 11). This may be related to an early stage
of malignant transformation, not yet detectable morphologically, and emphasizes the high sensitivity of 1H NMR
spectroscopy in elucidating characteristics of brain tumor metabolism. Copyright # 2005 John Wiley & Sons, Ltd.
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INTRODUCTION
1H NMR spectroscopy (1H MRS) has been used exten-
sively to characterize intracranial neoplasms in vivo.
Several detectable metabolites contribute to the distinc-
tion between normal brain and brain tumors and help in
the investigation of metabolic alterations of different
tumor types.1–5 In vivo brain tumors show an increased
concentration of the total choline signal [tCho¼ the sum
of phosphocholine (PCho, a precursor of membrane
phospholipids), glycerophosphocholine (GPCho, a degra-
dation product of membrane phospholipids) and free
choline] and also the ratio of tCho over total creatine
[tCr¼ the sum of phosphocreatine (PCr) and creatine (Cr)]
compared with the contralateral brain hemisphere. This
has been taken to reflect greater membrane synthesis,
increased cellularity and rapid cell membrane turnover
during cell growth.6–10 Moreover, the in vivo 1H MRS
tCho signal and the ratio tCho/tCr are assumed to be
related to the degree of malignancy,2,3,11–13 whereas
some authors found these values to be non-discriminative
between low- and high-grade gliomas.10,14,15
The in vivo N-acetyl methyl signal at 2.01 ppm is
mainly attributed to N-acetylaspartate (NAA), which is
reduced in gliomas and mostly absent in meningiomas.16
As NAA serves as a marker of neural cell density, its
reduction is evidently caused by a loss of neural
cells.7,17,18 Cr decreases in highly malignant gliomas to
some extent and is low or not detectable in meningio-
mas.13,19,20 The lactate (Lac) signal can be observed in
brain tumors, but its association with highly malignant
tumors was not shown unequivocally.13
To clarify such in vivo findings, several parallel studies
were performed with spectral analysis of tissue extracts
obtained from biopsy specimens or after tumor re-
moval.10,12,14,21,22 Such investigations were helpful for
the clarification of resonance assignments and for the
validation of the quantification procedures of in vivo 1H
NMR data. Particularly the in vivo contributions to the
tCho signal are still controversial. The tCho concentra-
tion of the respective tissue volume analyzed in vitro was
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lower than expected from the in vivo data. Some authors
assumed this could at least partially be due to the loss of
mobile choline headgroups of the phospholipid phospha-
tidylcholine during the extraction procedure.20,23,24
In vitro 1H NMR studies have been reported for a wide
range of human brain tumors with different degrees of
malignancy. Owing to the higher magnetic field strength
of in vitro NMR systems, the sensitivity and spectral
resolution are greatly improved, increasing the number of
detectable metabolites. Hence further specifications of
abnormalities in tumor metabolism including less con-
centrated metabolites such as alanine (Ala), glutamine
(Gln) or myo-inositol (myo-Ino) have been reported.
With this spectral information, different tumor types
have been characterized and tumor malignancy has
been determined in gliomas.19,20,25–27
It is well known that low-grade gliomas often undergo
malignant transformation into tumors of higher malig-
nancy during their development of recurrence. The ma-
lignancy potential in terms of biological aggressiveness
in recurrent gliomas is considered to be that of malignant
gliomas, a situation which is associated with poor prog-
nosis as related to reduced survival times.3,13,28–30 The
comparison of metabolite profiles in tissue samples of
primary and recurrent gliomas with or without changes in
malignancy will therefore provide further insight into
mechanisms of malignant transformation. In the present
study, we hypothesized that tumor recurrence is accom-
panied by an evolving tumor metabolism, leading to
specific alterations of the metabolic tumor profile, and
that these metabolic alterations can be observed using
high resolution in vitro 1H NMR spectroscopy.
In the present 1H NMR study, biopsy specimens from
patients who had undergone surgical removal of brain
tumors on at least two occasions had been analyzed,
providing samples of primary tumors and their respective
recurrent tumors. The serial measurement of primary
and recurrent tumors from the same patients enabled us
to obtain biochemical information on an evolving
tumor metabolism. To the best of our knowledge, this is
the first in vitro 1H NMR study evaluating grading-




Tissue specimens of brain tumors were obtained from a
large tissue bank of brain tumor biopsies collected during
surgery at the Department of Neurosurgery, University of
Cologne. These neurosurgical samples had been taken
during conventional microsurgical operations for tumor
removal. Tumors were studied after informed consent of
the patients had been obtained according to the Helsinki
Declaration of ethical requirements.
Patient group profiles
Patient group profiles are given in Table 1. Samples of the
primary brain tumor and its first recurrence were avail-
able from all patients.
Specimens from 22 patients with astrocytomas were
examined. These patients were further divided into three
groups, depending on the grade of malignancy in the
recurrent tumor: World Health Organization (WHO)
grade II, III and IV, respectively. The first group (i)
comprised 11 patients with low-grade (WHO grade II)
primary astrocytomas without changes in histopathologi-
cal grading during recurrence. The second group (ii)
consisted of five patients with anaplastic (WHO grade
III) recurrences. The third group (iii) was based on six
patients with secondary glioblastoma (WHO grade IV),
but varying primary grades: four of them with anaplastic
and two with low-grade primary astrocytomas.
Furthermore, primary and recurrent tumors from 11
patients with primary glioblastomas (WHO grade IV) and
13 patients with meningiomas were investigated. Finally,
one sample of peritumoral, non-neoplastic human brain,
derived from part of the tissue removal of an oligoden-
droglioma, was investigated.
Sample preparation
All specimens were frozen in liquid nitrogen immediately
after excision and stored at 80C. Histopathological
Table 1. Patient group profiles, each patient contributing one primary and its first recurrent tumor
Tumor type Age (years)a Patients Recurrenceb Malignant transformationc
Astrocytomas (Grade II–IV)d 39 11 22 22 16 11
(i) GII ! GII 36 9 11 23 17 0
(ii) GII ! GIII 35 14 5 25 8 5
(iii) GII/III ! GIV 46 10 6 17 15 6
Glioblastomas (GIV) 58 9 11 10 6 —
Meningiomas (GII) 55 19 13 15 13 0
Astrocytomas are subdivided due to grading changes in recurrence, determined by WHO grading criteria (Grade II–IV).
aAge at time of primary surgery, mean SD.
bPostoperative intervals in months until second surgery, mean SD.
cNumber of malignant degenerations in recurrence, based on histopathological classifications.
dSubgroups according to histopathological grading in tumor recurrence; GIV comprises six secondary glioblastomas, evolved from prior
astrocytomas (GII–III).
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diagnosis was performed on 10mm thin cryostat sections
after hematoxylin–eosin staining and followed the WHO
classification system.31 Tissue samples were taken from
the same part of the tumor as used for the cryostat section
for histological analysis. The samples ranged from 50 to
150mg wet weight. Frozen tissue was immediately homo-
genized after addition of 6% chilled perchloric acid (0.2–
0.5mL, depending on tissue weight). After 20min of
storage on ice, samples were centrifuged at 16 000 g for
4min. The supernatant was collected and the pellet was
resuspended in perchloric acid and treated as described
above. The combined supernatant was carefully neutra-
lized with KOH, centrifuged to remove precipitated
KClO4, lyophilized and stored at 80C. All chemicals
used were obtained from Sigma (Deisenhofen, Germany).
1H NMR spectroscopy
All spectra were recorded on a WM300 high-resolution
NMR spectrometer (Bruker, Karlsruhe, Germany). The
sample tube was spun at 15Hz. Proton spectra were
collected at 300.09MHz.
Perchloric acid (PCA) extracts of the tissues were
redissolved in 0.5mL of deuterium oxide and the pH
was checked for neutrality. The samples were then
transferred into a 5mm diameter NMR tube. The spectral
parameters were as follows: 360 acquisitions, 16K data
points, 90 pulse angle, 2200Hz sweep width, relaxation
delay 1.0 s and acquisition time 3.71 s, resulting in a
repetition time of 4.71 s and an experimental averaging
time of 28min. 3-(Trimethylsilyl)propionic acid (TSP)
was used as an external standard for sample quantifica-
tion; chemical shift referencing was achieved relative to
the creatine signal at 3.04 ppm. No line broadening was
applied. To assess potential T1-dependent signal damping
before integration, comparison of the signal intensities of
fully relaxed spectra (TR¼ 30 s) with the respective
signal intensities using a repetition time of 4.71 s was
performed. No significant T1-dependent saturation re-
garding the signal intensities of the relevant compounds
(Gly, tCho, tCr, Glu, Gln, Ala) was observed. The
integration values were normalized to the number of
contributing protons per molecule and to tissue weight.
Quantification was performed by comparing the inte-
grated TSP signal with the signal of interest in the tumor
spectrum after baseline correction. Absolute concentra-
tions are given as means SD in mol/g wet weight.
Assignment of resonances
All signal assignments in the 1H NMR spectra were made
by adding pure substances of individual metabolites to
sample solution and comparing the peak heights before
and after addition. The resulting values (ppm) were con-
firmed by comparison with literature assignments.23,32,33
Statistical analysis
One-way-analysis of variance (ANOVA) was used to
perform an F-test for the determination of statistical
significance among the primary tumors of the three tumor
types by group means. Groupings between primary and
recurrent tumors within a tumor type were compared at
the level of the individual metabolites using a two-tailed




In good agreement with epidemiological studies34 on
large groups, the average age of patients in the astrocy-
toma group is approximately 16 and 18 years younger
than that of patients with meningiomas and glioblastomas,
respectively (Table 1). Patients with secondary glioblas-
tomas, evolved from prior astrocytomas, are somewhat
older at time of primary surgery. The postoperative inter-
val represents the time elapsed between the first surgery
on the brain tumor and operation on the recurrent tumor.
The mean postoperative interval of astrocytomas is about
1 year longer than that of glioblastomas, whereas this
period is slightly decreased in secondary glioblastomas.
Early recurrence of meningiomas may be mainly influ-
enced by incomplete excision owing to the location of the
tumor. Increased histological malignancy grade, referring
to malignant transformation, was present in 11 recurrent
tumors from 22 patients with primary astrocytomas,
including six secondary glioblastomas.
Normal brain
The high-field region (1.0–4.5 ppm) of 1H MR spectra
obtained from non-neoplastic peritumoral tissue is shown
in Fig. 1. In agreement with histology, the tissue sample
showed spectroscopic features as described for normal
brain,12,23,35,36 with a wide range of metabolites (Table 2).
The main features of normal brain as opposed to brain
tumor spectra were high concentrations of NAA, Asp and
myo-Ino, in parallel with low concentrations of Ala, Gly
and tCho; Lac was greatly increased because of the
unavoidable time of anaerobic glycolysis during tissue
excision and was therefore of no discriminative value.
Distinction between primary astrocytomas,
glioblastomas and meningiomas
Differences between the representative spectra of pri-
mary astrocytomas, glioblastomas and meningiomas
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were as follows (Tables 3 and 4). Characteristic features
of glioblastomas were significantly increased concentra-
tions of Ala (p¼ 0.0048) and metabolite ratios of Gly/tCr
and Glu/Gln (p¼ 0.0001 and 0.0043, respectively) com-
pared with the respective levels in astrocytomas. The
signal multiplet of myo-Ino was well resolved in most of
the astrocytoma spectra, in contrast to glioblastomas, but
quantification could not be performed accurately enough
because of overlapping resonances and poor signal re-
solution in glioblastoma samples.
Figure 1. 1H NMR spectrum of a sample of peritumoral non-neoplastic brain tissue. Note the prominent NAA
signal, representative of neuronal tissue, and the well-resolved Asp andmyo-Ino signals. The high Lac signal is due to
the anaerobic glycolysis during the short period between tissue excision at the time of surgery and freezing in liquid
nitrogen. Assignment of all resonance signals follows the compilation in Table 2
Table 2. Resonance assignments of 1H NMR spectra to metabolites (chemical shift in ppm; ppm values in bold were
used for quantification of the respective metabolites)
Metabolite Abbreviation Chemical shifta Spin–spinb Proton(s)
1 N-Acetylaspartate NAA 2.02; 4.39 S; DD CH3; CH2
2 Lactate Lac 1.33; 4.11 D; Q CH3; CH
3 Creatine tCr 3.04; 3.93 S; S N-CH3; CH2
4 myo-Inositol myo-Ino 3.54; 3.29; 4.05 M; T; T H1,H3; H5; H2
5 scyllo-Inositol — 3.35 S —
6 Taurine Tau 3.42; 3.27 T; T N-CH2; S-CH2
7 Glycine Gly 3.56 S CH2
8 Aspartate Asp 2.80 M CH2
9 Gamma-aminobutyrate GABA 1.91; 2.30; 3.01 M; T; T CH2; CH3; CH2
10 Choline group tCho 3.20–3.24 — —
11 Glycerophosphocholine GPCho 3.24 S N-(CH3)3
12 Phosphocholine PCho 3.22 S N-(CH3)3
13 Free choline fCho 3.20 S N-(CH3)3
14 Glutamine Gln 2.46; 2.13; 3.77 DT; M; M CH2; CH2; CH
15 Glutamate Glu 2.35; 2.09; 3.75 DT; M; M CH2; CH2; CH
16 Alanine Ala 1.48; 3.76 D; D CH; CH3
17 Acetate — 1.92 S CH3
18 Succinate Succ 2.40 S CH2
Unidentified signal — 3.72 S —
aChemical shift is measured with respect to 3-trimethylsilylpropionate (TSP) at 0 ppm.
bThe letter appended to the chemical shift values indicates whether the signal is a singlet (S), doublet (D), doublet of a doublet (DD), triplet (T),
doublet of a triplet (DT), quadruplet (Q) or multiplet (M).32
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Relative to astrocytomas, meningiomas showed sig-
nificantly higher levels of Ala (p¼ 0.0048) and reduced
contents of tCr, reflected by all ratios with respect to tCr.
Absolute concentrations of Glu (p¼ 0.02) and the ratio
Glu/Gln (p¼ 0.0043) were significantly elevated in me-
ningiomas relative to astrocytomas. No signals of myo-
Ino were detectable in meningiomas.
There was no noticeable difference in tCho concentra-
tion between the three tumor types. The significantly
increased ratio of tCho/tCr (p¼ 0.0001) in meningiomas
relative to gliomas was mainly attributed to the dimin-
ished tCr content.
Distinction between primary and
recurrent meningiomas
The spectrum of the recurrent meningioma (Fig. 2)
showed features nearly identical with those of the pri-
mary tumor, with a lowered or undetectable Cr signal and
a prominent doublet of Ala as the two main features of
meningiomas. The absence of myo-Ino allowed the
quantification of even low Gly levels. No significant
differences between primary and recurrent tumors of 13
patients could be detected.
Distinction between primary and recurrent
glioblastomas
Proton spectra of glioblastomas showed high variability
between primary tumor and recurrence, often accompa-
nied by substantial deterioration of signal-to-noise ratios,
whereas the Gly signal often remained significant (Fig. 3).
Both spectra showed notable Ala and Glu signals. There
were no significant detectable differences between pri-
mary and recurrent glioblastomas of 11 patients.
Distinction between primary and
recurrent astrocytomas
Representative spectra of a primary and its recurrent
astrocytoma, without malignant transformation in histo-
pathological grading, are displayed in Fig. 4. Remarkable
alterations between these spectra were characterized as
follows: signals of Gly, Ala and Glu were increased, the
ratio tCho/tCr was moderately elevated and the myo-Ino
multiplet was unchanged.
Proton spectra of 22 patients with recurrent astrocyto-
mas showed distinctive differences in comparison with
their primary occurrences (Fig. 5). The signals of Gly
Table 3. Metabolite concentrations of primary and recurrent human brain tumors (lmol/g, mean SD)
Metabolite Astrocytomas (n¼ 22)a Glioblastomas (n¼ 11) Meningiomas (n¼ 13)
Primary Recurring Primary Recurring Primary Recurring
Gly 0.28 0.42 1.21 1.84 3.26 7.83 5.46 14.4 1.74 2.51 2.51 2.85
tCho 1.20 1.28 1.71 1.76 2.08 3.00 1.86 2.31 1.45 1.03 1.74 1.54
tCr 2.55 4.05 2.03 2.26 1.57 1.67 2.28 2.09 0.70 0.51 1.32 1.19
Glu 0.19 0.43 0.89 1.21 1.56 2.51 3.04 3.96 2.15 2.79 3.90 4.42
Gln 3.94 4.65 4.82 4.77 4.25 5.21 4.11 5.12 6.20 4.02 6.69 6.71
Ala 0.34 0.48 0.77 0.81 2.45 4.23 1.88 2.70 3.45 2.85 3.69 3.60
Gly/tCr 0.19 0.31 1.00 1.46 1.43 1.40 1.32 2.11 3.06 2.17 2.79 2.57
tCho/tCr 0.60 0.29 1.08 0.54 1.07 0.46 0.87 0.34 2.68 2.07 2.22 1.57
Ala/tCr 0.25 0.38 0.93 1.18 1.36 0.82 1.13 1.13 5.74 4.03 4.56 4.66
Glu/Gln 0.06 0.16 0.27 0.32 0.58 0.63 0.61 0.53 0.42 0.43 0.47 0.37
aPrimary tumors WHO Grade I/II–III, recurrences WHO Grade II–IV.
Table 4. p-Values for comparisons between primary tumors and their recurrences of three tumor types and among
primary tumors to distinguish among the three tumor types
Metabolite Astrocytomas Glioblastomas Meningiomas Comparisons among primary tumor types
Gly 0.029a 0.312 0.477 0.1613
tCho 0.034a 0.578 0.671 0.4513
tCr 0.364 0.158 0.710 0.2209
Glu 0.015a 0.278 0.239 0.0209;b for astrocytomas–meningiomas
Gln 0.360 0.959 0.514 0.4009
Ala 0.002a 0.354 0.997 0.0048;b for astrocytomas–glioblastomas; astrocytomas–meningiomas
Gly/tCr 0.033a 0.773 0.695 0.0001;b for all three comparisons
tCho/tCr 0.001a 0.183 0.506 0.0001;b for astrocytomas–meningiomas; glioblastomas–meningiomas
Ala/tCr 0.009a 0.594 0.681 0.0001;b for astrocytomas–meningiomas; glioblastomas–meningiomas
Glu/Gln 0.016a 0.876 0.790 0.0043;b for astrocytomas–glioblastomas; astrocytomas–meningiomas
aPaired t-test, two-tailed, p< 0.05 (primary vs recurrent tumor).
bOne-way ANOVA, F-test, p< 0.05 (primary tumors of the three tumor types).
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(p¼ 0.029), tCho (p¼ 0.034), Glu (p¼ 0.015) and Ala
(p¼ 0.002) increased with statistical significance. The
same holds true for ratios of Ala, Gly and tCho over tCr
and of Glu over Gln (p¼ 0.009, 0.033, 0.001 and 0.016,
respectively).
As shown above, Ala, Gly/tCr and Glu/Gln were like-
wise significantly increased in primary tumors of glio-
blastomas relative to astrocytomas. To establish whether
the observable changes in recurrent astrocytomas were
due to samples with increased grading in recurrence, the
22 patients with astrocytomas were further divided into
three subgroups according to histopathological grading
changes of the respective recurrence (Table 1).
Recurrences of low-grade astrocytomas:
grading independent changes in
metabolite patterns
Despite unchanged grading, the recurrent low-grade
astrocytomas (n¼ 11) showed similar metabolite patterns
to the more malignant gliomas. In the case of the ratio
tCho/tCr, which is a commonly used metabolite ratio for
in vivo 1H MRS measurements of brain tumors, a sig-
nificant increase (p¼ 0.0051) from the low-grade pri-
mary (0.5 0.15) to their low-grade recurrent tumors
(1.11 0.55) was found (Fig. 6). The same holds for
concentrations of Ala (0.24 0.36 vs 0.58 0.73 mmol/
g; p¼ 0.037) and Glu (0.0 vs 0.35 0.59 mmol/g;
p¼ 0.0032) with statistical significance. Thus, even in
recurrent low-grade astrocytomas, alterations of metabo-
lite patterns representative for high-grade gliomas were
observed.
DISCUSSION
The results of the present study emphasize the ability of
in vitro high-resolution proton NMR spectroscopy to
distinguish between different brain tumor tissue types.
Moreover, this approach facilitates the detection of subtle
changes in tumor metabolism towards higher malignancy
Figure 2. 1H NMR spectra of a sample of primary and recurrent tumor of a 35-year-old patient presenting with a
meningioma. Surgery of the recurrence was performed 4 months after removal of the primary tumor. Note the
prominent Ala signal and the diminutive tCr signal. Assignment of all resonance signals follows the compilation in
Table 2
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even in recurrent low-grade astrocytomas without histo-
pathological grading changes, reflecting an evolving
tumor metabolism. In contrast to previous in vitro studies,
we found evidence that the widely accepted use of in vivo
1H MRS tCho characteristics, indicative of tumor malig-
nancy and progression, could be confirmed by in vitro 1H
MRS, if serial measurements are accomplished.
Mean values found in previous studies using in vitro 1H
MRS on non-neoplastic brain, gliomas of various grading
classes and meningiomas10,12,20,35–37 are compiled in
Table 5. Interestingly, the range of literature values for
low-grade gliomas covers our mean values of tumor grou-
ping into low-grade primary vs low-grade recurrent tumor.
Therefore, inclusion of primary and recurrent tumor status
in low-grade gliomas may contribute to the scatter of
values found for this tumor entity in the literature.
Non-neoplastic peritumoral brain
The interpretation of spectral characteristics derived from
peritumoral non-neoplastic brain tissue should be done
with great care. One has to keep in mind that metabolic
alterations in the vicinity of tumor tissue cannot be ruled
out. This can be due to peritumoral edema or even
histologically non-perceptible changes that could influ-
ence spectral features. However, the spectrum obtained in
the present study showed features fully identical with
those of brain tissue obtained during seizure surgery23,35
and also of other samples of peritumoral brain tissue.12,21
In contrast to all examined tumor samples, high contents
of NAA and well-resolved signals of Asp were found.
NAA has been described by several groups7,12,32 as
being localized primarily in neurons and therefore it has
been proposed as a marker for neuronal density. Reduced
or absent levels of NAA in brain tumors as opposed to
normal brain were interpreted as a loss of neurons in the
tumor tissue. NAA has further been implicated as being
involved in the regulation of protein synthesis, myelin
production and metabolism of several neurotransmitters
such as Asp or N-acetylaspartyl glutamate.38 Only re-
cently, NAA was also found in oligodendrocyte–type 2
astrocyte (O-2A) progenitor cells,39 implying that NAA
may contribute at an early stage of brain development to
lipid synthesis by providing an important source of acetyl
groups.
Figure 3. 1H NMR spectra for a 44-year-old patient presenting with a glioblastoma. Operation of the
recurrence was performed 5 months later. The primary and recurrent tumor show pronounced Gly and Ala
signals, whereas myo-Ino is diminished. The remaining NAA signal is due to infiltrative growth of tumor tissue
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Asp is diminished in brain tumors but exhibits a well-
resolved signal in normal brain, reflecting the interdepen-
dence of NAA and Asp.23,24,32 The observable NAA and
Asp contents appearing in a brain tumor spectra in vitro are
considered as infiltrative growth of the tumor into adjacent
brain or as neuron residues within the tumor tissue.13,20,40,41
Myo-Ino is a further prominent signal in normal brain
spectra, and also in the spectra of low-grade gliomas.
Some authors suggest myo-Ino to be specific to glial
cells, but its role, apart from its biochemical relationship
to messenger inositol polyphosphates, or functional role
as cell osmoregulator is still unclear.42,43
Meningiomas
The discrimination of meningiomas from gliomas is most
easily achieved by the low or undetectable Cr content and
the prominent Ala doublet at 1.48 ppm in meningiomas.
Cr reduction and high Ala contents are also found in cell
cultures of normal meningeal cells.19 Hence a low Cr level
is not a sign of impaired energy supply but may be a result
of a different steady-state energy metabolism compared
with brain tissue.15 A further feature of meningiomas is
the absence of myo-Ino in comparison with gliomas.20
Patients examined in the present study experienced
recurrence after a mean of 15 months. Since malignant
transformation and infiltrative growth are rare, this short
recurrence period may be influenced by incomplete
Figure 4. 1H NMR spectra for a 52-year-old patient presenting with a low-grade astrocytoma and with
recurrence of unchanged grading after 2.5 years. The spectrum of the recurrence (below) shows elevated Gly
and Ala signals, whereas myo-Ino is unchanged. The ratio tCho/tCr is slightly increased
Figure 5. Metabolite concentrations and ratios
(mean SD) in 22 patients with astrocytomas (Grade II–
IV), reflecting an evolving tumor metabolism in individual
tumor progression. Statistical significance is indicated with
*; for p-values see Table 4
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resection due to tumor localization. The spectra between
primary and recurrent meningiomas were strikingly un-
changed, indicating no metabolic alterations in the course
of the recurrence development.
Glioblastomas
Glioblastomas are known to be the most heterogeneous
tumors in the brain, with a variable content of necrosis,
cell density, vascular proliferation and surrounding
edema.29 Accordingly, the spectral patterns of primary
and recurrent glioblastomas showed high variability,
extending from indications of diffusely infiltrative
growth, reflected by high NAA and Asp contents, to
signs of tissue necrosis, with diminished metabolite
signals. Nevertheless, glioblastomas could be distin-
guished from astrocytomas by specific metabolic pat-
terns. The most noticeable peculiarity is the Gly singlet at
3.56 ppm.14,20,36 It is suggested that intermediates of the
more active glycolytic pathway in tumors bring about an
increased Gly concentration, involving phosphoglycerate
and serine.44 Since the scatter of absolute values was
rather high, focus was on the relative Gly concentration
(normalized to tCr), which was found to be statistically
significantly different from that of astrocytomas. Further-
more, the concentration of Ala and the ratio Glu/Gln were
significantly higher in glioblastomas than in astrocyto-
mas. Florian et al. described increased Ala and Glu
contents in defective or transformed cells due to enzy-
matic alterations in the glycolytic pathway in brain
tumors.33 Neither tCho nor the tCho/tCr ratio was found
to be discriminative between primary tumors of astro-
cytomas and glioblastomas.
Figure 6. Intraindividual alterations of the tCho/tCr ratio as a function of malignant transformation
in primary and recurrent astrocytomas, as based on the WHO histopathological classification. The
consistently increasing ratios display no distinction according to tumor grade. Low-grade astrocyto-
mas without malignant transformation (n¼11, left panel) showed a statistically significant, elevated
ratio for the recurrent tumor (p¼0.0051), which is not yet visible in histological analysis based on
morphological criteria
Table 5. 1H MRS quantitative results derived from previous studies (PCA extraction of tissue extracts) of
peritumoral brain, low-grade (Grades I–II) and high-grade (Grades III–IV) gliomas and meningiomas (lmol/g)
Metabolite Normal brain Grade I–II Own valuesa Grade III–IV Own valuesa Meningiomas Own valuesa
Gly 0.66–0.82b,f,g 0.91–1.77b,e,f 0.12–0.70 1.53–5.01b,e 0.45–5.46 1.01–1.60b,e 1.74–2.51
tCho 0.57–1.86b,c,e–g 0.68–1.77b,c,e,f 1.03–1.70 1.19–2.18b,c,e 0.82–2.08 0.81–1.92b,c,e 1.45–1.74
tCr 2.17–10.76b–g 1.94–7.80b–f 1.8–2.62 1.85–3.65b–e 1.13–2.28 0.42–1.45b–e 0.70–1.32
Ala 0.14–0.91b,e–g 0.37–1.01b,e,f 0.24–0.58 0.92–3.25b,e 0.79–2.45 1.27–3.1b,e 3.45–3.69
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The postoperative interval was <1 year, reflecting the
tendency for fast tumor progression. No significance in
metabolite concentrations or relative values could be
ascertained between primary and recurrent glioblastomas.
Astrocytomas
In the present study, astrocytomas reoccurred after a
mean of 22 months, presenting further malignant degen-
eration in half of the investigated cases. The number of
observed transformations is in good agreement with
previous studies on the frequency of malignant transfor-
mation in gliomas.28
Earlier in vitro 1H MRS investigations12,20,21,36,37,41
focusing solely on the distinction of low- and high-grade
gliomas are in full agreement with the differences found
in the present study. Here, however, these differences are
solidified by basing them on the intra-individual distinc-
tion between primary and recurrent astrocytomas:
concentrations of Ala, tCho, Gly, Glu and ratios of Gly,
tCho and Ala to tCr and of Glu to Gln increased
significantly between primary and recurrent gliomas. In
the case of Ala and Gly to tCr and Glu to Gln ratios,
the values were also found to be discriminative inter-
individually, on comparing primary tumors of astrocyto-
mas and glioblastomas.
Choline findings
The in vivo tCho characteristics were not found to be
directly and unambiguously transferable to the in vitro
findings. For once, there is still no consensus about the
chemical species responsible for the tCho peak in vivo. In
vitro 1H MRS measurements of brain tumor tissue
showed lower tCho contents than expected from in vivo
measurements performed prior to tumor excision.10,14
This was related, at least partly, to significant amounts
of glycerophospholipids with mobile choline headgroups
under in vivo conditions.20,45 Furthermore, the tCho
content, as determined by in vitro 1H MRS, does not
seem to be a reliable parameter either for the distinction
of normal brain tissue from brain tumors or for the
differentiation of low-grade from high-grade glio-
mas.10,12,33,36 In fact, our study confirmed the unrelia-
bility of the tCho content and the ratio tCho/tCr for the
distinction between primary occurrences of astrocytomas
and glioblastomas.
Specific issues concerning recurrence
discriminations
Interestingly, in contrast to the doubtful diagnostic rele-
vance of tCho as discussed above, serialmeasurements of
tCho content and tCho/tCr ratio showed a statistically
significant increase on comparing primary and recurrent
astrocytomas. Moreover, even low-grade astrocytomas
(Fig. 6) showed a significantly elevated metabolite ratio
of tCho/tCr in recurrence despite an unchanged WHO
grading (p¼ 0.0051). Since histopathological grading of
the respective sample volume yielded no change in tumor
categorization, the detected spectroscopic features are
believed to occur at an early stage of malignant transfor-
mation, which is not yet observable morphologically but
which is detectable in metabolic alterations. Support for
this view comes from serial in vivo 1H MRS measure-
ments after gamma knife radiosurgery of malignant
gliomas by Graves et al.46 The increase in Cho signal
indicative of tumor recurrence preceded a deterioration of
MR imaging criteria by 1–2 months. Tedeschi et al. 3
investigated patients with gliomas repeatedly, using in
vivo 1H MRS, in order to discriminate clinically stable
brain tumors from those progressing as a result of low- to
high-grade malignant transformation. Analysis of the
tCho signal intensity showed a clear increase in all
progressive cases or in recurrences of previously treated
tumors. This was associated by the authors with reduced
survival times, indicating that categorization by means of
serial 1H MRS studies was accurate.
In a study by our group published previously, we
investigated human brain tumor samples using a double
extraction method, which enabled us to quantify both
water-soluble and lipophilic spectral Cho-containing
components of the same sample volume.47 Evaluation
of phospholipid profiles in recurrent astrocytomas
showed increased malignancy in comparison with their
primary occurrence, namely, the relative concentration of
phosphatidylcholine (PtdCho), the most abundant mem-
brane lipid and the major component in Cho metabolism,
was 15% higher in recurrent astrocytomas than their
primary tumors (p¼ 0.0103), whereas the second Cho-
containing phospholipid sphingomyelin (SM) decreased
by 23% (p¼ 0.0314). The same composition was found
on comparing samples of primary astrocytomas and
primary glioblastomas: PtdCho was found to be 34%
higher in primary glioblastomas than in primary astro-
cytomas (p¼ 0.0003), whereas SM decreased by 50%
(p¼ 0.0061). We concluded that the alterations in phos-
pholipid composition in recurrent astrocytomas were
related to malignant transformation. Our present 1H
NMR investigations of the water-soluble tissue fraction
provide insights into the choline metabolism during
malignant transformation. We found that the ratio tCho/
tCr was significantly increased in recurrent astrocytomas
and also in the comparison between primary astrocyto-
mas and primary glioblastomas.
CONCLUSIONS
The consecutive assessment of tumor metabolism by
in vitro 1H MRS studies of individual patients by means
F.-G. LEHNHARDT ET AL.
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of serial measurements, eliminates influences of inter-
individual tumor heterogeneity. Using this diagnostic
approach, remarkable peculiarities of an evolving tumor
metabolism even at an early stage of malignant transfor-
mation are detectable. In contrast to several previous in
vitro studies but in good agreement with previous in vivo
studies, the present investigation led to a correlation of
the tCho signal and the ratio tCho/tCr with tumor
progression in gliomas. Further in vitro MRS studies
should be performed to elucidate the interrelation of
cell membrane and cytosolic choline metabolism during
malignant transformation.
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